Antibodies

This webinar shows a 2-step mAb purification workflow and compares multimodal options for polishing. See how these methods can achieve high-purity products.

Current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have reduced the severity of the coronavirus disease 2019 (COVID-19). However, the drastic and quick evolution of the virus poses challenges to the development of durable and efficacious therapeutics for vaccine and antibody developers alike. See how the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit speeds up the qualitative measurement of neutralizing antibodies (NAbs) against new SARS-CoV-2 variants, removing a roadblock in COVID-19 therapeutic development.

Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous. However, significant advances in antibody technology such as phage display have enabled fully human antibodies to be developed from animal-free libraries for just about any antigen.

Develop new assays in just one day with the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit. See how in this webinar.

Monoclonal antibody (mAb) purification methods often involve the use of resin-based chromatography. In this video, we compare a three-step mAb purification workflow, which uses Nuvia Ion Exchange Resins post–Protein A capture, to a two-step purification workflow, which includes a Protein A capture step followed by a mixed-mode chromatography step using Nuvia aPrime 4A Resin, a hydrophobic anion exchange resin. We present an additional two-step purification approach using Protein A resin followed by a calcium affinity cation exchange media, CHT Ceramic Hydroxyapatite XT Media. The results of both studies demonstrate that a high purity product can be attained using one fewer unit operation than traditional workflows.

Recombinant antibodies, CAR-T Cell Therapy Development, CAR-T Cell Therapy, Monoclonal Antibody Generation, custom antibodies, cell and gene therapy development, bioanalysis, biosimilar, immunogenicity, drug monitoring, antibody drug conjugate.

Bispecific antibodies (bsAbs) are an important addition to the immuno-oncology toolbox. Designed to recognize two distinct epitopes, bsAbs have enhanced binding, specificity, and efficacy compared to current monovalent antibody therapeutics, making them exciting candidates for more targeted cancer treatments. Learn about bsAbs and how our tools can help scientists with their research on therapeutic candidates.

In the day-to-day pressures of a research environment, it is natural to want to generate important data as quickly as possible. However, there are real benefits in ensuring that the antibody you have picked is the best for your experiment and spending time aliquoting and titrating your antibodies. Bio-Rad recently launched a free Antibody Advice Guide to equip scientists with the knowledge to get the best out of their experiments with antibodies. Read on for five examples of valuable information that you will learn from the guide, helping you generate publication-ready data.

The lack of reproducibility in research has been a source of frustration for scientists. Learn why antibody validation is critical for ensuring specificity and what validation methods Bio-Rad is implementing. Our scientists validate the performance of antibodies through CRISPR-Cas9 gene editing by knockout (KO), siRNA knockdown (KD), and immunoprecipitation followed by mass spectrometry (IP-MS).

See how an antibody expression service provider, Evitria (Zurich, Switzerland) optimized and expanded their antibody production services using the NGC Chromatography Systems to meet the growing demands of their customers.